Arno Therapeutics Inc (ARNI) financial statements (2020 and earlier)

Company profile

Business Address 200 ROUTE 31 NORTH
FLEMINGTON, NJ 08822
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2016
TTM
12/31/2015
12/31/2014
12/31/2013
12/31/2012
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 082711
Cash and cash equivalents 082711
Prepaid expense and other current assets0
Other undisclosed current assets 000 
Total current assets: 082711
Noncurrent Assets
Property, plant and equipment 0000
Deposits noncurrent assets 0000
Deferred costs    2
Total noncurrent assets: 0002
TOTAL ASSETS: 082713
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities 1132
Accounts payable 1132
Debt 00  
Due to related parties   00
Deferred revenue and credits 0000
Other undisclosed current liabilities 3112
Total current liabilities: 4243
Noncurrent Liabilities
Long-term debt and lease obligation 00  
Capital lease obligations 00  
Liabilities, other than long-term debt 573621
Derivative instruments and hedges, liabilities 573621
Other undisclosed noncurrent liabilities    0
Total noncurrent liabilities: 573622
Total liabilities: 994025
Stockholders' equity
Stockholders' equity attributable to parent, including: (9)(1)(13)(12)
Common stock 0000
Additional paid in capital 85817738
Accumulated deficit (93)   
Warrants and rights outstanding    12
Other undisclosed stockholders' equity attributable to parent  (82)(90)(62)
Total stockholders' equity: (9)(1)(13)(12)
TOTAL LIABILITIES AND EQUITY: 082713

Income statement (P&L) ($ in millions)

9/30/2016
TTM
12/31/2015
12/31/2014
12/31/2013
12/31/2012
Operating expenses (13)(21)(17)(11)
Operating loss: (13)(21)(17)(11)
Nonoperating income (expense) 229(23)(4)
Debt instrument, convertible, beneficial conversion feature  8  
Other nonoperating income (expense) 229(4)3
Interest and debt expense (0)(0)(2)(6)
Net income (loss): (12)8(42)(21)
Other undisclosed net income attributable to parent 0026
Net income (loss) available to common stockholders, basic: (12)8(40)(14)
Dilutive securities, effect on basic earnings per share   40 
Net income (loss) available to common stockholders, diluted: (12)80(14)

Comprehensive Income ($ in millions)

9/30/2016
TTM
12/31/2015
12/31/2014
12/31/2013
12/31/2012
Net income (loss): (12)8(42)(21)
Comprehensive income (loss), net of tax, attributable to parent: (12)8(42)(21)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: